1.	Sequential Vaccinations in Prostate Cancer Patients Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 030176, 03-C-0176, NCI-03-C-0176, NCI-5911, 5911, NCT00062153, NCT00060528
2.	Phase II Randomized Study of Vaccinia-PSA-TRICOM Vaccine, Fowlpox-PSA-TRICOM Vaccine, and Sargramostim (GM-CSF) Versus Empty Vector Control in Patients With Metastatic Androgen-Independent Prostate Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0309014, THERION-TBC-PRO-002, NCT00078585
3.	Vaccine Therapy and GM-CSF in Treating Patients With Prostate Cancer That Progressed After Surgery and/or Radiation Therapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000422430, U10CA021115, ECOG-E9802, E9802, NCT00108732
4.	Phase II Randomized Study of Docetaxel and Prednisone With Versus Without Vaccine Therapy Comprising Vaccinia-PSA(L155)-TRICOM and Fowlpox-PSA(L155)-TRICOM in Patients With Castration-Resistant Metastatic Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1809, E1809, E1809, NCT01145508
5.	Phase I Pilot Study of Vaccine Therapy Comprising Priming Vaccinations of Vaccinia-PSA-TRICOM and Recombinant Fowlpox GM-CSF (rF-GM-CSF) Followed By Boosting Vaccinations of Fowlpox-PSA-TRICOM With or Without rF-GM-CSF in Patients With Progressive or Locally Recurrent Prostate Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-05-C-0017, NCI-6066, 6066, NCT00098449
6.	Phase I Study of Vaccine Therapy Comprising Vaccinia-PSA-TRICOM Vaccine and Fowlpox-PSA-TRICOM Vaccine in Combination With Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody Ipilimumab (MDX-010) and Sargramostim (GM-CSF) in Patients With Androgen-Independent Metastatic Prostate Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-05-C-0167, 7207, NCI-7207, NCT00124670